Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous Cinryze

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionComplement 1 (C1) esterase inhibitor
Molecular Target Complement 1 (C1) esterase
Mechanism of ActionComplement inhibitor
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationAngioedema
Indication DetailsPrevent attacks of hereditary angioedema (HAE); Treat attacks of hereditary angioedema (HAE)
Regulatory Designation
Partner Halozyme Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$4,283.0M

$4,209.0M

$74.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today